BenevolentAI Investor Conference Presentation Deck
Using our platform for wider societal
benefit
Identified a COVID-19 treatment now approved
for use by the FDA
RAPID
Identified baricitinib as a treatment in just 48 hours, published
research in The Lancet in Feb 2020
NOVEL
Our technology and Al workflows identified a previously unknown
antiviral mechanism (¹)
EFFECTIVE
COV-BARRIER trial showed baricitinib reduces mortality by 38% in
hospitalised patients(2), and by 46% in ventilated or ECMO patients (3)
FDA
FDA approved the baricitinib to
treat COVID-19 in May 2022(4) after
first granting EUA in Nov 2020 (5)
Lilly
Led to equity investment from
Eli Lilly
DNDi
Drugs for Neglected Diseases initiative
Non-commercial
collaboration
→ Focused on Dengue fever - a
major healthcare burden
→ Aims to deliver biological
targets and drug repurposing
candidates
→ Experimental validation in
progress - 6 assaysView entire presentation